EGEpameinondas Gousopoulos

Epameinondas Gousopoulos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Epameinondas Gousopoulos has a total of 112 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bulging of the Masseter Muscle Following Botulinum Neurotoxin Type A Injection

    by Lukas Naef, Epameinondas Gousopoulos, Florian Alexander Huber, Pietro Giovanoli

    Summary: Botulinum neurotoxin toxin type A is widely used in the management of facial paralysis to reduce synkinesis and improve facial symmetry. Although the masseter muscle is not innervated by the facial nerve, aberrant reinnervation may lead to abnormal activity requiring treatment. We report the case of a 48-year-old woman with long-standing, partially regenerated right-sided facial palsy who developed paradoxical masseter muscle bulging following botulinum neurotoxin toxin type A injection. After a single injection targeting masseter hypertonicity, the patient exhibited a visible bulge during clenching. Ultrasound imaging revealed superficial muscle bulging associated with intramuscular septations. Uneven toxin diffusion caused by internal tendinous barriers within the masseter muscle was identified as the most likely mechanism. This case highlights the importance of understanding masseter anatomy and applying precise injection techniques to minimize adverse effects and optimize therapeutic outcomes.

  • Open Access

    Longitudinal evaluation of lymphatic reconstruction: Ten-year practice and outcome data from a single institution

    by Carlotta Barbon, Carlotta Imholz, Carmen E. Zurfluh, Jennifer A. Watson, Epameinondas Gousopoulos, Diana Vetter, Christian A. Gutschow, Alexandru Grigorean, Pietro Giovanoli, Lisanne Grünherz, et al.

  • Open Access

    Transcriptomics- and 3D imaging–based characterization of the lymphatic vasculature in human skin

    by Aline Bauer, Lito Zambounis, Ioannis Kritikos, Almut Lütge, Amélie Sabine, Coraline Heron, Milena Petkova, Costanza Giampietro, Katharina Blatter, Salvatore Daniele Bianco, et al.

    Afferent lymphatic vessels (LVs) are present in most vascularized tissues and exert important immune and drainage functions, yet human afferent LVs remain poorly studied. Performing single-cell RNA sequencing of lymphatic endothelial cells (LECs) from human skin and subcutaneous adipose tissue, we identified various LEC subsets, including two valve LEC populations located on the upstream and downstream sides of the valve leaflets. The cell adhesion molecule CD24 emerged as a specific marker of upper valve leaflet LECs in human skin and contributed to lymphatic valve development in murine mesentery. Three-dimensional imaging further revealed several unique features of the human dermal lymphatic network, including a high proportion of LYVE-1+ pre-collecting vessels containing intraluminal valves, virtually no collectors, and absence of lymphatic muscle cell coverage. Moreover, LECs in blind-ended capillaries and around valves in pre-collectors displayed mixed junctional and morphological phenotypes. These findings reveal key differences between human and murine dermal afferent lymphatics and provide a deeper understanding of human lymphatic-related (patho)physiological processes.


  • Open Access

    Therapeutic Modulation of Meningeal Lymphatics: A Systematic Review of Preclinical Evidence Across Neurological Disorders

    by Sedef Kollarik, Sophie Katharina Humer, Carmen Elena Zurfluh, Epameinondas Gousopoulos, Nicole Lindenblatt

    Meningeal lymphatic vessels (MLVs) have emerged as critical modulators of cerebral homeostasis, immune surveillance, and metabolic clearance. Their dysfunction is increasingly implicated in the pathogenesis of neurodegenerative and neuroinflammatory conditions. This systematic review aimed to synthesize current preclinical evidence on the therapeutic modulation of MLVs across animal models of neurological disease, focusing on pathological, behavioral, and immunological outcomes. We conducted the literature search in the PubMed, Embase, Web of Science, and Scopus databases in accordance with PRISMA guidelines and included peer-reviewed, controlled preclinical studies investigating interventions aimed at enhancing meningeal lymphatic drainage in neurological disease models. Risk of bias was assessed using Covidence’s quality assessment template, supported by the SYRCLE Risk of Bias tool. Given the heterogeneity of models and interventions, a qualitative synthesis was performed. Therapeutic strategies were consistently associated with improved MLV structure and function, enhanced clearance of neurotoxic proteins, reduced neuroinflammation, and improved cognitive and motor performance across the disease models. Thus, enhancing meningeal lymphatic drainage represents a promising preclinical therapeutic approach for a wide spectrum of neurological conditions. Future research should aim to standardize methodologies, explore sex- and age-specific effects, and accelerate translation into human trials.


  • Open Access

    Reconstruction of the subungual region for tumors of the thumb: Outcomes of the reverse, dorsoulnar flap

    by Esin Rothenfluh, Epameinondas Gousopoulos, Esther Vögelin, Radu Olariu, Maurizio Calcagni

  • Primäre Lymphödeme bei Kindern und Jugendlichen: chirurgische Therapie

    by Lisanne Grünherz, Epameinondas Gousopoulos, Nicole Lindenblatt

  • Open Access

    Anti-CTLA4 treatment reduces lymphedema risk potentially through a systemic expansion of the FOXP3+ Treg population

    by Stefan Wolf, Matiar Madanchi, Patrick Turko, Maija Hollmén, Sonia Tugues, Julia von Atzigen, Pietro Giovanoli, Reinhard Dummer, Nicole Lindenblatt, Cornelia Halin, et al.

    Secondary lymphedema is a common sequel of oncologic surgery and presents a global health burden still lacking pharmacological treatment. The infiltration of the lymphedematous extremities with CD4+T cells influences lymphedema onset and emerges as a promising therapy target. Here, we show that the modulation of CD4+FOXP3+CD25+regulatory T (Treg) cells upon anti-CTLA4 treatment protects against lymphedema development in patients with melanoma and in a mouse lymphedema model. A retrospective evaluation of a melanoma patient registry reveals that anti-CTLA4 reduces lymphedema risk; in parallel, anti-CTLA4 reduces edema and improves lymphatic function in a mouse-tail lymphedema model. This protective effect of anti-CTLA4 correlates with a systemic expansion of Tregs, both in the animal model and in patients with melanoma. Our data thus show that anti-CTLA4 with its lymphedema-protective and anti-tumor properties is a promising candidate for more diverse application in the clinics.


  • Open Access

    Evaluation of the Effect of Botulinum Toxin A on the Lymphatic Endothelial Cells

    by Mauro Vasella, Stefan Wolf, Lisanne Grünherz, Bong-Sung Kim, Nicole Lindenblatt, Pietro Giovanoli, Epameinondas Gousopoulos

    Introduction: Botulinum toxin A (BoTA) is a neurotoxin formed by Clostridium botulinum, with a broad medical application spectrum. While the primary effect of BoTA is on the muscles, the effects of BoTA in other systems including the blood vasculature have already been examined, revealing unexpected actions. However, no studies exist to the best of our knowledge regarding the potential effects of BoTA on the lymphatic vascular system, possessing a critical role in health and disease. Isolated human lymphatic endothelial cells (LECs) were cultured in dedicated in vitro culture systems. The analysis including imaging and cell culture approaches as well as molecular biology techniques is performed to examine the LEC alterations occurring upon exposure to different concentrations of BoTA. Materials and Methods: Human LECs were cultured and expanded on collagen-coated petri dishes using endothelial basal medium and the commercial product Botox from Allergan as used for all our experiments. Harvested cells were used in various in vitro functional tests to assess the morphologic and functional properties of the BoTA-treated LECs. Gene expression analysis was performed to assess the most important lymphatic system-related genes and pathways. Results: Concentrations of 1, 5 or 10 U of BoTA did not demonstrate a significant effect regarding the proliferation and migration capacity of the LECs versus untreated controls. Interestingly, even the smallest BoTA dose was found to significantly decrease the cord-like-structure formation capacity of the seeded LECs. Gene expression analysis was used to underpin possible molecular alterations, suggesting no significant effect of BoTA in the modification of gene expression versus the starvation medium control. Conclusion: LECs appear largely unaffected to BoTA treatment, with an isolated effect on the cord-like-structure formation capacity. Further work needs to assess the effect of BoTA on the smooth-muscle-cell-covered collecting lymphatic vessels and the possible aesthetic implications of such an effect, due to edema formation. Level of Evidence V: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.


  • Open Access

    CD112 Supports Lymphatic Migration of Human Dermal Dendritic Cells

    by Neda Haghayegh Jahromi, Anastasia-Olga Gkountidi, Victor Collado-Diaz, Katharina Blatter, Aline Bauer, Lito Zambounis, Jessica Danielly Medina-Sanchez, Erica Russo, Peter Runge, Gaetana Restivo, et al.

    Dendritic cell (DC) migration from peripheral tissues via afferent lymphatic vessels to draining lymph nodes (dLNs) is important for the organism’s immune regulation and immune protection. Several lymphatic endothelial cell (LEC)-expressed adhesion molecules have thus far been found to support transmigration and movement within the lymphatic vasculature. In this study, we investigated the contribution of CD112, an adhesion molecule that we recently found to be highly expressed in murine LECs, to this process. Performing in vitro assays in the murine system, we found that transmigration of bone marrow-derived dendritic cells (BM-DCs) across or adhesion to murine LEC monolayers was reduced when CD112 was absent on LECs, DCs, or both cell types, suggesting the involvement of homophilic CD112–CD112 interactions. While CD112 was highly expressed in murine dermal LECs, CD112 levels were low in endogenous murine dermal DCs and BM-DCs. This might explain why we observed no defect in the in vivo lymphatic migration of adoptively transferred BM-DCs or endogenous DCs from the skin to dLNs. Compared to murine DCs, human monocyte-derived DCs expressed higher CD112 levels, and their migration across human CD112-expressing LECs was significantly reduced upon CD112 blockade. CD112 expression was also readily detected in endogenous human dermal DCs and LECs by flow cytometry and immunofluorescence. Upon incubating human skin punch biopsies in the presence of CD112-blocking antibodies, DC emigration from the tissue into the culture medium was significantly reduced, indicating impaired lymphatic migration. Overall, our data reveal a contribution of CD112 to human DC migration.